Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research
Larimar Therapeutics (Nasdaq: LRMR) announced three poster presentations at the upcoming International Congress for Ataxia Research (ICAR) in London, U.K., from November 12-15, 2024. The presentations will showcase data from the company's nomlabofusp Phase 1 studies and Phase 2 dose exploration study for Friedreich's ataxia treatment.
Nomlabofusp is a novel protein replacement therapy designed to deliver frataxin to mitochondria, addressing the root cause of Friedreich's ataxia. The presentations will cover:
- Effects of nomlabofusp on tissue frataxin levels, plasma lipid profiles, and gene expression
- Disease characteristics and tissue frataxin concentrations in adult patients
- Prediction of tissue frataxin levels with long-term nomlabofusp administration
Dr. Russell Clayton, Chief Medical Officer of Larimar, will give an oral presentation on November 14, 2024.
Larimar Therapeutics (Nasdaq: LRMR) ha annunciato tre presentazioni poster al prossimo Congresso Internazionale per la Ricerca sulla Atassia (ICAR) che si svolgerà a Londra, Regno Unito, dal 12 al 15 novembre 2024. Le presentazioni mostreranno dati dagli studi Phase 1 e dallo studio di esplorazione della dose Phase 2 di nomlabofusp per il trattamento dell'atassia di Friedreich.
Nomlabofusp è una nuova terapia di sostituzione proteica progettata per fornire frataxina ai mitocondri, affrontando la causa principale dell'atassia di Friedreich. Le presentazioni tratteranno:
- Effetti di nomlabofusp sui livelli di frataxina nei tessuti, profili lipidici plasmatici ed espressione genica
- Caratteristiche della malattia e concentrazioni di frataxina nei tessuti nei pazienti adulti
- Previsione dei livelli di frataxina nei tessuti con somministrazione a lungo termine di nomlabofusp
Il Dr. Russell Clayton, Direttore Medico di Larimar, offrirà una presentazione orale il 14 novembre 2024.
Larimar Therapeutics (Nasdaq: LRMR) anunció tres presentaciones en cartel en el próximo Congreso Internacional de Investigación sobre Ataxia (ICAR) en Londres, Reino Unido, del 12 al 15 de noviembre de 2024. Las presentaciones mostrarán datos de los estudios Phase 1 y del estudio de exploración de dosis Phase 2 de nomlabofusp para el tratamiento de la ataxia de Friedreich.
Nomlabofusp es una nueva terapia de reemplazo de proteínas diseñada para entregar frataxina a las mitocondrias, abordando la causa raíz de la ataxia de Friedreich. Las presentaciones cubrirán:
- Efectos de nomlabofusp en los niveles de frataxina en tejidos, perfiles lipídicos plasmáticos y expresión génica
- Características de la enfermedad y concentraciones de frataxina en tejidos en pacientes adultos
- Predicción de niveles de frataxina en tejidos con administración a largo plazo de nomlabofusp
El Dr. Russell Clayton, Director Médico de Larimar, ofrecerá una presentación oral el 14 de noviembre de 2024.
Larimar Therapeutics (Nasdaq: LRMR)는 2024년 11월 12일부터 15일까지 영국 런던에서 열리는 제2회 국제 운동실조 연구 회의(ICAR)에서 세 가지 포스터 발표를 할 예정이라고 발표했습니다. 발표에서는 nomlabofusp 1상 연구와 2상 용량 탐색 연구에 대한 데이터를 선보일 것입니다.
Nomlabofusp는 프라탁신을 미토콘드리아에 전달하기 위해 설계된 새로운 단백질 대체 요법으로, 프리드레이히 운동실조의 근본 원인을 다루고 있습니다. 발표 내용은 다음과 같습니다:
- nomlabofusp가 조직 내 프라탁신 수준, 혈장 지방 프로필 및 유전자 발현에 미치는 영향
- 성인 환자의 질병 특성과 조직 내 프라탁신 농도
- 장기 nomlabofusp 투여에 따른 조직 내 프라탁신 수준 예측
라리마르의 최고 의료 책임자인 러셀 클레이튼 박사가 2024년 11월 14일 구두 발표를 할 예정입니다.
Larimar Therapeutics (Nasdaq: LRMR) a annoncé trois présentations d'affiches lors du prochain Congrès international de recherche sur l'ataxie (ICAR) à Londres, Royaume-Uni, du 12 au 15 novembre 2024. Les présentations mettront en lumière des données sur les études de phase 1 et l'étude d'exploration de dose de phase 2 de nomlabofusp pour le traitement de l'ataxie de Friedreich.
Nomlabofusp est une thérapie innovante de remplacement de protéines conçue pour délivrer de la frataxine aux mitochondries, s'attaquant à la cause fondamentale de l'ataxie de Friedreich. Les présentations couvriront :
- Les effets de nomlabofusp sur les niveaux de frataxine dans les tissus, les profils lipidiques plasmatiques et l'expression génétique
- Les caractéristiques de la maladie et les concentrations de frataxine dans les tissus chez les patients adultes
- La prévision des niveaux de frataxine dans les tissus avec l'administration à long terme de nomlabofusp
Dr. Russell Clayton, Directeur médical de Larimar, présentera une communication orale le 14 novembre 2024.
Larimar Therapeutics (Nasdaq: LRMR) hat drei Posterpräsentationen auf dem bevorstehenden Internationalen Kongress für Ataxieforschung (ICAR) in London, Vereinigtes Königreich, vom 12. bis 15. November 2024 angekündigt. Die Präsentationen werden Daten aus den Phase-1-Studien und der Phase-2-Dosierungsstudie von nomlabofusp zur Behandlung der Friedreich-Ataxie vorstellen.
Nomlabofusp ist eine neue Proteinersatztherapie, die entwickelt wurde, um Frataxin in die Mitochondrien zu liefern und so die Hauptursache der Friedreich-Ataxie anzugehen. Die Präsentationen werden folgende Punkte behandeln:
- Wirkungen von nomlabofusp auf die Frataxinspiegel im Gewebe, die Lipidprofile im Plasma und die Genexpression
- Krankheitsmerkmale und Frataxin-Konzentrationen im Gewebe bei erwachsenen Patienten
- Vorhersage der Frataxinspiegel im Gewebe bei langfristiger Anwendung von nomlabofusp
Dr. Russell Clayton, Chief Medical Officer von Larimar, wird am 14. November 2024 eine mündliche Präsentation halten.
- Larimar Therapeutics is presenting data from multiple clinical studies at a major international conference
- The company's novel protein replacement therapy, nomlabofusp, targets the root cause of Friedreich's ataxia
- Presentations cover various aspects of nomlabofusp's effects and potential long-term benefits
- None.
BALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s nomlabofusp Phase 1 studies and Phase 2 dose exploration study, some of which has been previously disclosed, will be presented at the annual International Congress for Ataxia Research (ICAR) being held November 12-15, 2024 in London, U.K. Nomlabofusp is a novel protein replacement therapy designed to address the root cause of Friedreich’s ataxia by delivering frataxin to mitochondria.
Larimar will present three posters during the conference, one of which will also be presented as an oral presentation. The poster presentations are as follows:
- Effect of nomlabofusp administration on tissue frataxin levels, plasma lipid profiles, and gene expression in patients with Friedreich’s ataxia
- Oral presentation by Dr. Russell Clayton, Chief Medical Officer of Larimar Therapeutics on Thursday November 14, 2024, at 5:07 PM CT
- Disease characteristics and tissue frataxin concentrations in adults with Friedreich’s ataxia participating in nomlabofusp interventional studies
- Prediction of tissue frataxin levels with long term administration of nomlabofusp in adults with Friedreich’s ataxia using modeling and simulations
About Nomlabofusp (CTI-1601)
Nomlabofusp is a recombinant fusion protein intended to deliver human frataxin to the mitochondria of patients with Friedreich’s ataxia who are unable to produce enough of this essential protein. Nomlabofusp has been granted Rare Pediatric Disease designation, Fast Track designation and Orphan Drug designation by the U.S. Food and Drug Administration (FDA), Orphan Drug Designation by the European Commission, and a PRIME designation by the European Medicines Agency. The FDA recently selected nomlabofusp to participate in the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program, a new milestone-driven program designed to accelerate development of novel therapies intended to address an unmet medical need for rare diseases.
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp (CTI-1601), is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
FAQ
What is Larimar Therapeutics presenting at the International Congress for Ataxia Research (ICAR) 2024?
When and where is the International Congress for Ataxia Research (ICAR) 2024 taking place?
What is nomlabofusp and how does it work for Friedreich's ataxia?
Who will be giving the oral presentation for Larimar Therapeutics (LRMR) at ICAR 2024?
